560 results on '"Oliveira, Andre M."'
Search Results
2. Fragment-Based Drug Design in Lead Discovery
3. EWSR1::POU2AF3(COLCA2) Sarcoma: An Aggressive, Polyphenotypic Sarcoma With a Head and Neck Predilection
4. Energy-to-Peak Static Output Control for Continuous-Time Hidden Markov Jump Linear Systems
5. Differential Linear Matrix Inequalities in Optimal and Robust Sampled-Data Filtering
6. Reduced-order energy-to-peak filtering for hidden Markov jump linear systems
7. Fusion‐driven cutaneous and superficial mesenchymal and adnexal tumors—A clinicopathologic and molecular study of 15 cases, including a novel case of ACTB::ZMIZ2‐rearranged adnexal carcinoma
8. Morphologically malignant nodular fasciitis with CALD1-USP6 fusion
9. Static Output Energy-to-Peak Control for Semi-Markov Jump Linear Systems With Phase-Type Distributions and Hidden Modes
10. Malignant Tenosynovial Giant Cell Tumor: The True “Synovial Sarcoma?” A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes
11. Network-Aware Design of State-Feedback Controllers for Linear Wireless Networked Control Systems
12. Supplementary Video S1 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
13. Supplementary Figure S7 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
14. FIGURE 6 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
15. Supplementary Table S1 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
16. FIGURE 1 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
17. FIGURE 2 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
18. FIGURE 5 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
19. FIGURE 4 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
20. FIGURE 7 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
21. Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
22. FIGURE 3 from Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma
23. Data from Natural killer cell activation by Ubiquitin-specific protease 6 (USP6) mediates tumor suppression in Ewing sarcoma
24. Supplementary Figure S7 from Natural killer cell activation by Ubiquitin-specific protease 6 (USP6) mediates tumor suppression in Ewing sarcoma
25. Supplementary Table S1 from Natural killer cell activation by Ubiquitin-specific protease 6 (USP6) mediates tumor suppression in Ewing sarcoma
26. Supplementary Video S1 from Natural killer cell activation by Ubiquitin-specific protease 6 (USP6) mediates tumor suppression in Ewing sarcoma
27. USP6 activation in nodular fasciitis by promoter-swapping gene fusions
28. Environmental exposures as a risk factor for fibrolamellar carcinoma
29. Transcriptomic and immunophenotypic characterization of two cases of adamantinoma‐like Ewing sarcoma of the thyroid gland
30. Supplemental Figure 2 from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
31. Supplemental Figure 1 from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
32. Supplemental Figure 6 from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
33. Data from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
34. Supplemental Table 1 from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
35. Supplemental Figure 3 from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
36. Suppl Data FIgure legends from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
37. Supplemental Figure 4 from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
38. Supplemental Figure 5 from USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
39. Supplementary Data from Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation
40. Data from Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation
41. Supplemental Figure 2 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
42. Data from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
43. Supplemental Table 3 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
44. Supplemental Figure 1 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
45. Supplemental Figure 3 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
46. Supplemental Table 1 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
47. Supplemental Figure 4 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
48. Supplemental Table 2 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
49. Supplemental Table 4 from Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
50. USP6 genetic rearrangements in cellular fibroma of tendon sheath
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.